Company
Headquarters: Chengdu, China
Employees: 1,513
CEO: Mr. Yang Dong
HK$7.83 Billion
HKD as of July 1, 2024
US$1.00 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. The company primarily offers two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; medical services in the areas of gynecology, urology, and internal medicine; ambulatory surgery center facilities services; and ancillary medical services. Further, it offers pre-implantation genetic screening testing services; and property holding and management services. Jinxin Fertility Group Limited was founded in 2003 and is headquartered in Chengdu, China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Jinxin Fertility Group Ltd has the following listings and related stock indices.
Stock: HKEX: 1951 wb_incandescent
Stock: FSX: 3NX wb_incandescent
Stock: OTC: JXFGF wb_incandescent